Discontinuing or reducing renin-angiotensin-aldosterone system inhibitor treatment may have negative outcomes for patients with hyperkalemia, but it is a common practice in many clinics, according ...

Hyperkalemia in type 2 diabetes occurred less often with GLP-1 receptor agonists in routine care than dipeptidyl peptidase-4 (DPP-4) inhibitors, a large observational study in Sweden showed. Over ...

Hyperkalemia may be considered a common occurrence in patients with chronic kidney disease, particularly in those with heart failure or diabetes, published data show.“ [T]he increased risk of ...

Spironolactone, used for heart failure and high blood pressure, offers no cardiovascular benefit for dialysis patients and ...

Hyperkalemia is common among patients with chronic kidney disease (CKD), but some medications such as SGLT2 inhibitors may lower the risk.

While the perceived need for new therapies for hyperkalemia is relatively low compared to a number of other conditions in nephrology, interest is high ...